In this week’s View, Dr. Eagle discusses the newly published table that lists drug-drug interactions with the anti-viral agent Paxlovid, used in treating COVID-19, then looks at an analysis of the LIFE Trial Run-In that examines the tolerability of sacubitril/valsartan in patients with advanced heart failure. Finally, Dr. Eagle explores the CABANA randomized clinical trial and its insights into the cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy in atrial fibrillation.